At the beginning of the year, Dr. Springer had a net worth of $2.1 billion due to his early investment in Moderna.
In 2014, he founded biotech firm Morphic Holding, the lead program of which is an oral treatment for inflammatory bowel disease patients, according to a July 8 report from Forbes.
On July 8, Eli Lilly announced plans to acquire Morphic for $3.2 billion. Dr. Springer still owns about 16% of Morphic’s stock and stands to make $435 million when the deal closes.
The acquisition announcement led to a surge in Morphic’s share price, which rose by 75% to $55.79 on Monday afternoon. The sale price also marks a 280% gain for Dr. Springer since the firm went public at $15 a share in July 2019.
Dr. Springer has also founded or been an early investor in at least three other publicly traded biotech firms.
He first backed Moderna in 2010 with a $5 million investment and currently owns about 3% of the firm.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.